Ovarian, breast, prostate and pancreatic cancers (PARPi) [DNA, Germline]
Applicable to any lab undertaking germline molecular testing of BRCA1 and BRCA2 genes in the context of PARPi prescription, using genomic DNA.
Prostate cancer (PARPi) [Plasma, cfDNA]
Pilot EQA scheme. Applicable to any lab undertaking molecular testing of BRCA1 and BRCA2 in the context of PARPi prescription, using cfDNA from plasma.
Ovarian and Prostate Cancer (PARPi) [Tissue, Somatic]
Applicable to any lab undertaking somatic molecular testing of BRCA1, BRCA2 and other Homologous Recombination Repair (HRR) genes in the context of PARPi prescription, using FFPE tissue.
Pharmacogenetics (DPYD / UGT1A1 only)
Applicable to all labs undertaking molecular testing of DPYD and/or UGT1A1 pharmacogenetic markers for drug response and efficacy.
Pharmacogenetics (panel testing)
Applicable to all labs undertaking panel based molecular testing of pharmacogenetic markers for drug response and efficacy.
Phenylketonuria (PKU)
Applicable to all labs undertaking molecular genetic testing in this disorder.
